Clinical Trial

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Protocol Amendment History 3 changes
notable Trial sites expanded: 33 -> 36 locations 2026-08-13
critical Primary endpoint(s) modified 2026-07-19
notable Primary completion pushed: 2026-03-17 -> 2026-10-20 2026-04-21
Trial Details
NCT Number NCT05875168
Lead Sponsor Daiichi Sankyo
Conditions Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment 590 participants
Start Date 2023-08-18
Primary Completion 2026-10-20 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12